DNA vaccination against foot-and-mouth disease via electroporation: Study of molecular approaches for enhancing VP1 antigenicity

Journal of Gene Medicine

Volumn 8, Issue 9, 2006, Pages 1182-1191

  Kim, Suk Am ^a,g   Liang, Chi Ming ^b   Cheng, Ivan Chen ^c   Cheng, Yung Chih ^a   Chiao, Ming Tsang ^a   Tseng, Chia Jen ^a   Lee, Fan ^d   Jong, Ming Hwa ^d   Tao, Mi Hua ^e   Yang, Ning Sun ^a,f,g   Liang, Shu Mei ^a,g  

^a AGRICULTURAL BIOTECHNOLOGY RESEARCH CENTER   (Taiwan)

^b INSTITUTE OF BIOLOGICAL CHEMISTRY   (Taiwan)

^c ANIMAL TECHNOLOGY INSTITUTE TAIWAN   (Taiwan)

^d FISHERIES RESEARCH INSTITUTE   (Taiwan)

^e INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^g ProteomeTech Inc   (South Korea)

Author keywords

Capsid protein; DNA vaccination; Electroporation immunogenicity; FMDV

Indexed keywords

CAPSID PRECURSOR POTEIN; CAPSID PROTEIN; COMPLEMENTARY DNA; DNA VACCINE; FOOT AND MOUTH DISEASE VACCINE; NEUTRALIZING ANTIBODY; PROTEIN VP1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG ANTIGENICITY; ELECTROPORATION; EXPRESSION VECTOR; FEMALE; FOOT AND MOUTH DISEASE; GENE CONSTRUCT; GENE DELIVERY SYSTEM; GENE THERAPY; HAMSTER; IMMUNE RESPONSE; IMMUNIZATION; MOLECULAR GENETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; TH2 CELL; VACCINATION;

ANIMALIA; FOOT-AND-MOUTH DISEASE VIRUS; MIRIDAE;

EID: 33749235740     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.941     Document Type: Article

References (62)

1. Rueckert RR. Picornaviridae: the viruses and their replication. In Virology, Fields BM, Knipe DM, Howley PH. (eds). Lippincott-Raven: Philadephia, 1996; 609-654.
2. Acharya R, Fry E, Stuart D, Fox G, Rowlands D, Brown F. The three-dimensional structure of foot-and-mouth disease virus at 2.9 A resolution.. Nature 1989; 337: 709-716.
3. Belsham GJ, McInerney GM, Ross-Smith N. Foot-and-mouth disease virus 3C protease induces cleavage of translation initiation factors eIF4A and eIF4G within infected cells. J Virol 2000; 74: 272-280.
4. Rweyemamu MM, Terry G, Pay TW. Stability and immunogenicity of empty particles of foot-and-mouth disease virus. Arch Virol 1979; 59: 69-79.
5. Bittle JL, Houghten RA, Alexander H, et al. Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature 1982; 298: 30-33.
6. Strohmaier K, Franze R, Adam KH. Location and characterization of the antigenic portion of the FMDV immunizing protein. J Gen Virol 1982; 59: 295-306.
7. Carrillo C, Wigdorovitz A, Trono K, et al. Induction of a virus-specific antibody response to foot and mouth disease virus using the structural protein VP1 expressed in transgenic potato plants. Viral Immunol 2001; 14: 49-57.
8. Shieh JJ, Liang CM, Chen CY, et al. Enhancement of the immunity to foot-and-mouth disease virus by DNA priming and protein boosting immunization. Vaccine 2001; 19: 4002-4010.
9. Abrams CC, King AM, Belsham GJ. Assembly of foot-and-mouth disease virus empty capsids synthesized by a vaccinia virus expression system. J Gen Virol 1995; 76: 3089-3098.
10. Brown F, Benkirane N, Limal D, et al. Delineation of a neutralizing subregion within the immunodominant epitope (GH loop) of foot-and-mouth disease virus VP1 which does not contain the RGD motif. Vaccine 1999; 18: 50-56.
11. DiMarchi R, Brooke G, Gale C, Cracknell V, Doel T, Mowat N. Protection of cattle against foot-and-mouth disease by a synthetic peptide. Science 1986; 232: 639-641.
12. Taboga O, Tami C, Carrillo E, et al. A large-scale evaluation of peptide vaccines against foot-and-mouth disease: lack of solid protection in cattle and isolation of escape mutants. J Virol 1997; 71: 2606-2614.
13. Petit MC, Benkirane N, Guichard G, et al. Solution structure of a retro-inverso peptide analogue mimicking the foot-and-mouth disease virus major antigenic site. Structural basis for its antigenic cross-reactivity with the parent peptide.. J Biol Chem 1999; 274: 3686-3692.
14. Harrison SC. Picornaviruses. Finding the receptors.. Nature 1989; 338: 205-206.
15. Mateu MG, Martinez MA, Capucci L, et al. A single amino acid substitution affects multiple overlapping epitopes in the major antigenic site of foot-and-mouth disease virus of serotype C. J Gen Virol 1990; 71: 629-637.
16. Becker Y. Need for cellular and humoral immune responses in bovines to ensure protection from foot-and-mouth disease virus (FMDV) - a point of view. Virus Genes 1994; 8: 199-214.
17. Collen T, Dimarchi R, Doel TR. A T cell epitope in VP1 of foot-and-mouth disease virus is immunodominant for vaccinated cattle. J Immunol 1991; 146: 749-755.
18. Collen T, Doel TR. Heterotypic recognition of foot-and-mouth disease virus by cattle lymphocytes. J Gen Virol 1990; 71: 309-315.
19. Garcia-Valcarcel M, Doel T, Collen T, Ryan M, Parkhouse RM. Recognition of foot-and-mouth disease virus and its capsid protein VP1 by bovine peripheral T lymphocytes. J Gen Virol 1996; 77: 727-735.
20. Saiz JC, Rodriguez A, Gonzalez M, Alonso F, Sobrino F. Heterotypic lymphoproliferative response in pigs vaccinated with foot-and-mouth disease virus. Involvement of isolated capsid proteins.. J Gen Virol 1992; 73: 2601-2607.
21. Liu MA, Ulmer JB. Gene-based vaccines. Mol Ther 2000; 1: 497-500.
22. Robinson HL, Torres CA. DNA vaccines. Semin Immunol 1997; 9: 271-283.
23. Yang NS, Wang JH, Lin KF, et al. Comparative studies of the capsid precursor polypeptide P1 and the capsid protein VP1 cDNA vectors for DNA vaccination against foot-and-mouth disease virus. J Gene Med 2005; 7: 708-717.
24. Ward G, Rieder E, Mason PW. Plasmid DNA encoding replicating foot-and-mouth disease virus genomes induces antiviral immune responses in swine. J Virol 1997; 71: 7442-7447.
25. Chinsangaram J, Beard C, Mason PW, Zellner MK, Ward G, Grubman MJ. Antibody response in mice inoculated with DNA expressing foot-and-mouth disease virus capsid proteins. J Virol 1998; 72: 4454-4457.
26. Beard C, Ward G, Rieder E, Chinsangaram J, Grubman MJ, Mason PW. Development of DNA vaccines for foot-and-mouth disease, evaluation of vaccines encoding replicating and non-replicating nucleic acids in swine. J Biotechnol 1999; 73: 243-249.
27. Benvenisti L, Rogel A, Kuznetzova L, Bujanover S, Becker Y, Stram Y. Gene gun-mediate DNA vaccination against foot-and-mouth disease virus. Vaccine 2001; 19: 3885-3895.
28. Cedillo-Barron L, Foster-Cuevas M, Belsham GJ, Lefevre F, Parkhouse RM. Induction of a protective response in swine vaccinated with DNA encoding foot-and-mouth disease virus empty capsid proteins and the 3D RNA polymerase. J Gen Virol 2001; 82: 1713-1724.
29. Huang H, Yang Z, Xu Q, et al. Recombinant fusion protein and DNA vaccines against foot and mouth disease virus infection in guinea pig and swine. Viral Immunol 1999; 12: 1-8.
30. Wong HT, Cheng SC, Chan EW, et al. Plasmids encoding foot-and-mouth disease virus VP1 epitopes elicited immune responses in mice and swine and protected swine against viral infection. Virology 2000; 278: 27-35.
31. Drew DR, Lightowlers M, Strugnell RA. Humoral immune responses to DNA vaccines expressing secreted, membrane bound and non-secreted forms of the Tania ovis 45W antigen. Vaccine 2000; 18: 2522-2532.
32. Fomsgaard A. HIV-1 DNA vaccines. Immunol Lett 1999; 65: 127-131.
33. Xiang ZQ, Spitalnik SL, Cheng J, Erikson J, Wojczyk B, Ertl HC. Immune responses to nucleic acid vaccines to rabies virus. Virology 1995; 209: 569-579.
34. Boyle JS, Koniaras C, Lew AM. Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization. Int Immunol 1997; 9: 1897-1906.
35. Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 1998; 16: 867-870.
36. Widera G, Austin M, Rabussay D, et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000; 164: 4635-4640.
37. Selby M, Goldbeck C, Pertile T, Walsh R, Ulmer J. Enhancement of DNA vaccine potency by electroporation in vivo. J Biotechnol 2000; 83: 147-152.
38. Kadowaki S, Chen Z, Asanuma H, Aizawa C, Kurata T, Tamura S. Protection against influenza virus infection in mice immunized by administration of hemagglutinin-expressing DNAs with electroporation. Vaccine 2000; 18: 2779-2788.
39. Harlow EaDL. Monoclonal antibodies and growing hybridomas. In Antibodies: A Laboratory Manual, Harlow EaDL (ed). Cold Spring Habor Laboratory: New York. 1988; 139-281.
40. Mackrill JJ, Wilcox RA, Miyawaki A, Mikoshiba K, Nahorski SR, Challiss RA. Stable overexpression of the type-1 inositol 1,4,5-trisphosphate receptor in L fibroblasts: subcellular distribution and functional consequences. Biochem J 1996; 318: 871-878.
41. Liao KW, Chou WC, Lo YC, Roffler SR. Design of transgenes for efficient expression of active chimeric proteins on mammalian cells. Biotechnol Bioeng 2001; 73: 313-323.
42. Coloma MJ, Hastings A, Wims LA, Morrison SL. Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J Immunol Methods 1992; 152: 89-104.
43. Gronwald RG, Grant FJ, Haldeman BA, et al. Cloning and expression of a cDNA coding for the human platelet-derived growth factor receptor: evidence for more than one receptor class. Proc Natl Acad Sci U S A 1988; 85: 3435-3439.
44. Chardin P, McCormick F. Brefeldin A: the advantage of being uncompetitive. Cell 1999; 97: 153-155.
45. McKeever U, Barman S, Hao T, et al. Protective immune responses elicited in mice by immunization with formulations of poly(lactide-co-glycolide) microparticles. Vaccine 2002; 20: 1524-1531.
46. Howard KA, Li XW, Somavarapu S, et al. Formulation of a microparticle carrier for oral polyplex-based DNA vaccines. Biochim Biophys Acta 2004; 1674: 149-157.
47. Nimesh S, Goyal A, Pawar V, et al. Polyethylenimine nanoparticles as efficient transfecting agents for mammalian cells. J Control Release 2006; 110: 457-468.
48. Weeratna RD, McCluskie MJ, Xu Y, Davis HL. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 2000; 18: 1755-1762.
49. Yang B, Ugen KE, Srikantan V, et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 1993; 90: 4156-4160.
50. Wang CY, Chang TY, Walfield AM, et al. Effective synthetic peptide vaccine for foot-and-mouth disease in swine. Vaccine 2002; 20: 2603-2610.
51. Wong HT, Cheng SC, Sin FW, Chan EW, Sheng ZT, Xie Y. A DNA vaccine against foot-and-mouth disease elicits an immune response in swine which is enhanced by co-administration with interleukin-2. Vaccine 2002; 20: 2641-2647.
52. Sanz-Parra A, Jimenez-Clavero MA, Garcia-Briones MM, Blanco E, Sobrino F, Ley V. Recombinant viruses expressing the foot-and-mouth disease virus capsid precursor polypeptide (P1) induce cellular but not humoral antiviral immunity and partial protection in pigs. Virology 1999; 259: 129-134.
53. Sanz-Parra A, Vazquez B, Sobrino F, Cox SJ, Ley V, Salt JS. Evidence of partial protection against foot-and-mouth disease in cattle immunized with a recombinant adenovirus vector expressing the precursor polypeptide (P1) of foot-and-mouth disease virus capsid proteins. J Gen Virol 1999; 80: 671-679.
54. Wang JH, Liang CM, Peng JM, et al. Induction of immunity in swine by purified recombinant VP1 of foot-and-mouth disease virus. Vaccine 2003; 21: 3721-3729.
55. Logan D, Abu-Ghazaleh R, Blakemore W, et al. Structure of a major immunogenic site on foot-and-mouth disease virus. Nature 1993; 362: 566-568.
56. Parry NR, Barnett PV, Ouldridge EJ, Rowlands DJ, Brown F. Neutralizing epitopes of type O foot-and-mouth disease virus. II. Mapping three conformational sites with synthetic peptide reagents. J Gen Virol 1989; 70: 1493-1503.
57. Sobrino F, Blanco E, Garcia-Briones M, Ley V. Synthetic peptide vaccines: foot-and-mouth disease virus as a model. Dev Biol Stand 1999; 101: 39-43.
58. Briand JP, Benkirane N, Guichard G, et al. A retro-inverso peptide corresponding to the GH loop of foot-and-mouth disease virus elicits high levels of long-lasting protective neutralizing antibodies. Proc Natl Acad Sci USA 1997; 94: 12545-12550.
59. Brown F. Antibody recognition and neutralization of foot-and-mouth disease virus. Semin Virol 1995; 6: 243-248.
60. Yoon HA, Aleyas AG, George JA, et al. Cytokine GM-CSF genetic adjuvant facilitates prophylactic DNA vaccine against pseudorabies virus through enhanced immune responses. Microbiol Immunol 2006; 50: 83-92.
61. Mayr GA, O'Donnell V, Chinsangaram J, Mason PW, Grubman MJ. Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs. Vaccine 2001; 19: 2152-2162.
62. Balamurugan V, Renji R, Saba SN, Reddy GR, Gopalakrishna S, Suryanarayana VV. Protective immune response of the capsid precursor polypeptide (P1) of foot and mouth disease virus type 'O' produced in Pichia pastoris. Virus Res 2003; 92: 141-149.